Ischemic stroke in COVID-19 patients: Mechanisms, treatment, and outcomes in a consecutive Swiss Stroke Registry analysis.
COVID-19
SARS-CoV-2
ischemic stroke
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
25
11
2021
received:
02
10
2021
accepted:
26
11
2021
pubmed:
1
12
2021
medline:
15
2
2022
entrez:
30
11
2021
Statut:
ppublish
Résumé
Most case series of patients with ischemic stroke (IS) and COVID-19 are limited to selected centers or lack 3-month outcomes. The aim of this study was to describe the frequency, clinical and radiological features, and 3-month outcomes of patients with IS and COVID-19 in a nationwide stroke registry. From the Swiss Stroke Registry (SSR), we included all consecutive IS patients ≥18 years admitted to Swiss Stroke Centers or Stroke Units during the first wave of COVID-19 (25 February to 8 June 2020). We compared baseline features, etiology, and 3-month outcome of SARS-CoV-2 polymerase chain reaction-positive (PCR+) IS patients to SARS-CoV-2 PCR- and/or asymptomatic non-tested IS patients. Of the 2341 IS patients registered in the SSR during the study period, 36 (1.5%) had confirmed COVID-19 infection, of which 33 were within 1 month before or after stroke onset. In multivariate analysis, COVID+ patients had more lesions in multiple vascular territories (OR 2.35, 95% CI 1.08-5.14, p = 0.032) and fewer cryptogenic strokes (OR 0.37, 95% CI 0.14-0.99, p = 0.049). COVID-19 was judged the likely principal cause of stroke in 8 patients (24%), a contributing/triggering factor in 12 (36%), and likely not contributing to stroke in 13 patients (40%). There was a strong trend towards worse functional outcome in COVID+ patients after propensity score (PS) adjustment for age, stroke severity, and revascularization treatments (PS-adjusted common OR for shift towards higher modified Rankin Scale (mRS) = 1.85, 95% CI 0.96-3.58, p = 0.07). In this nationwide analysis of consecutive ischemic strokes, concomitant COVID-19 was relatively rare. COVID+ patients more often had multi-territory stroke and less often cryptogenic stroke, and their 3-month functional outcome tended to be worse.
Sections du résumé
BACKGROUND
Most case series of patients with ischemic stroke (IS) and COVID-19 are limited to selected centers or lack 3-month outcomes. The aim of this study was to describe the frequency, clinical and radiological features, and 3-month outcomes of patients with IS and COVID-19 in a nationwide stroke registry.
METHODS
From the Swiss Stroke Registry (SSR), we included all consecutive IS patients ≥18 years admitted to Swiss Stroke Centers or Stroke Units during the first wave of COVID-19 (25 February to 8 June 2020). We compared baseline features, etiology, and 3-month outcome of SARS-CoV-2 polymerase chain reaction-positive (PCR+) IS patients to SARS-CoV-2 PCR- and/or asymptomatic non-tested IS patients.
RESULTS
Of the 2341 IS patients registered in the SSR during the study period, 36 (1.5%) had confirmed COVID-19 infection, of which 33 were within 1 month before or after stroke onset. In multivariate analysis, COVID+ patients had more lesions in multiple vascular territories (OR 2.35, 95% CI 1.08-5.14, p = 0.032) and fewer cryptogenic strokes (OR 0.37, 95% CI 0.14-0.99, p = 0.049). COVID-19 was judged the likely principal cause of stroke in 8 patients (24%), a contributing/triggering factor in 12 (36%), and likely not contributing to stroke in 13 patients (40%). There was a strong trend towards worse functional outcome in COVID+ patients after propensity score (PS) adjustment for age, stroke severity, and revascularization treatments (PS-adjusted common OR for shift towards higher modified Rankin Scale (mRS) = 1.85, 95% CI 0.96-3.58, p = 0.07).
CONCLUSIONS
In this nationwide analysis of consecutive ischemic strokes, concomitant COVID-19 was relatively rare. COVID+ patients more often had multi-territory stroke and less often cryptogenic stroke, and their 3-month functional outcome tended to be worse.
Identifiants
pubmed: 34845794
doi: 10.1111/ene.15199
pmc: PMC9299927
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
732-743Subventions
Organisme : Schweizerische Herzstiftung
Informations de copyright
© 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Mol Neurobiol. 2020 Dec;57(12):4921-4928
pubmed: 32813238
Stroke. 2021 May;52(5):e117-e130
pubmed: 33878892
J Clin Med. 2021 Mar 01;10(5):
pubmed: 33804307
AJNR Am J Neuroradiol. 2020 Dec;41(12):2263-2268
pubmed: 32855182
J Neurol. 2020 Nov;267(11):3161-3165
pubmed: 32583054
Stroke. 2020 Sep;51(9):e219-e222
pubmed: 32684145
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
J Neurol Sci. 2020 Jul 15;414:116889
pubmed: 32416370
Eur Stroke J. 2018 Sep;3(3):220-226
pubmed: 31008352
Stroke. 2020 Aug;51(8):2540-2543
pubmed: 32466736
J Stroke Cerebrovasc Dis. 2020 Dec;29(12):105325
pubmed: 32992196
Stroke. 2020 Jul;51(7):2002-2011
pubmed: 32432996
Tex Heart Inst J. 2007;34(1):11-8
pubmed: 17420787
Stroke. 2021 May;52(5):1693-1701
pubmed: 33793320
Stroke. 2021 May;52(5):1895-1904
pubmed: 33794655
J Neurol Neurosurg Psychiatry. 2021 Mar;92(3):242-248
pubmed: 33154179
Int J Stroke. 2021 Feb;16(2):137-149
pubmed: 33103610
Cerebrovasc Dis. 2021;50(4):412-419
pubmed: 33784669
Stroke. 2021 Dec;52(12):3908-3917
pubmed: 34455823
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
JAMA Netw Open. 2021 Apr 1;4(4):e217498
pubmed: 33885771
Lancet. 2013 Feb 9;381(9865):496-505
pubmed: 23332146
Stroke. 2021 Jan;52(2):552-562
pubmed: 33406872
BMC Neurol. 2021 Jan 30;21(1):43
pubmed: 33514335
Stroke. 2020 Sep;51(9):e254-e258
pubmed: 32787707
Stroke. 2020 Sep;51(9):e227-e231
pubmed: 32757751
Lancet. 1998 Oct 17;352(9136):1245-51
pubmed: 9788453
Eur J Neurol. 2022 Mar;29(3):732-743
pubmed: 34845794
AJNR Am J Neuroradiol. 2020 Aug;41(8):1384-1387
pubmed: 32554425
Neurosci Lett. 2021 Jan 19;743:135564
pubmed: 33352277